US 12,344,610 B2
APOL1 inhibitors and methods of use
Patrick Sang Tae Lee, Walnut Creek, CA (US); Todd Jonathan August Ewing, Walnut Creek, CA (US); Adam Neil Reid, San Francisco, CA (US); Christopher Joseph Sinz, Walnut Creek, CA (US); Birong Zhang, Union City, CA (US); Sarah M. Bronner, Oakland, CA (US); David John Morgans, Jr., Los Altos, CA (US); Maarten Hoek, Belmont, CA (US); Victoria Anne Assimon, San Francisco, CA (US); Chris Ziebenhaus, San Francisco, CA (US); and Alexander Wayne Schammel, San Diego, CA (US)
Assigned to Maze Therapeutics, Inc., South San Francisco, CA (US)
Filed by Maze Therapeutics, Inc., South San Francisco, CA (US)
Filed on Mar. 26, 2024, as Appl. No. 18/617,266.
Application 18/617,266 is a continuation of application No. 18/098,070, filed on Jan. 17, 2023, granted, now 11,976,067.
Claims priority of provisional application 63/422,341, filed on Nov. 3, 2022.
Claims priority of provisional application 63/400,359, filed on Aug. 23, 2022.
Claims priority of provisional application 63/332,553, filed on Apr. 19, 2022.
Claims priority of provisional application 63/311,668, filed on Feb. 18, 2022.
Claims priority of provisional application 63/300,592, filed on Jan. 18, 2022.
Prior Publication US 2024/0400565 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/10 (2006.01); A61K 31/438 (2006.01); C07D 487/10 (2006.01); C07D 519/00 (2006.01); C07F 9/53 (2006.01)
CPC C07D 471/10 (2013.01) [C07D 487/10 (2013.01); C07D 519/00 (2013.01); C07F 9/5333 (2013.01); C07B 2200/05 (2013.01)] 20 Claims
 
1. A compound of formula (I-E):

OG Complex Work Unit Chemistry
or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:
ring A is a 5-10 membered heterocyclyl or a 5-10 membered heteroaryl, wherein the 5-10 membered heterocyclyl of ring A is optionally substituted with one or more Rb, and
the 5-10 membered heteroaryl of ring A is optionally substituted with one or more Rc;
m is an integer from 0 to 4;
p is an integer from 0 to 10;
R1, if present is, independently at each occurrence selected from the group consisting of halo, —CN, C1-6alkoxy, and C1-6alkyl, wherein
the C1-6alkoxy of R1 is optionally substituted with one or more halo, and
the C1-6alkyl of R1 is optionally substituted with one or more halo;
R2 is H, C1-6alkyl, C3-10cycloalkyl, or 3-15 membered heterocyclyl, wherein
the C1-6alkyl of R2 is optionally substituted with one or more deuterium, halo, —OH, —NH2, or C1-6alkoxy, and
the C3-10cycloalkyl of R2 is optionally substituted with one or more —OH;
R3, if present, is C1-6alkyl;
L1 is C1-6alkylene, wherein
the C1-6alkylene of L1 is optionally substituted with one or more deuterium or C1-6alkyl, and wherein
the C1-6alkyl is further optionally substituted with one or more —OH or C1-6alkoxy;
X2 is N or C (R5);
Rb is, independently at each occurrence, selected from the group consisting of —OH, halo, oxo, C1-6alkyl, —C(O)—C1-6alkyl, —C(O)—NH2, —C(O)—NH(C1-6alkyl), —C(O)—N(C1-6alkyl)2, —S(O)2—Ra, C3-10cycloalkyl, and 3-10 membered heterocyclyl, wherein
the C1-6alkyl of Rb is optionally substituted with one or more halo, OH, —S(O)2—C1-6alkyl, or C3-10cycloalkyl, and wherein
the C3-10cycloalkyl of the C1-6alkyl of Rb is further optionally substituted with one or more C1-6alkyl or —OH and
the C3-10cycloalkyl of Rb is optionally substituted with one or more —OH, C3-10-cycloalkyl, or C1-6alkyl, and wherein
the C1-6alkyl of the C3-10cycloalkyl of Rb is further optionally substituted with one or more —OH, deuterium, or halo;
Rc is, independently at each occurrence, selected from the group consisting of halo, C1-6alkyl, —C(O)—C1-6alkyl, —C(O)—NH2, —C(O)—NH(C1-6alkyl), —C(O)—N(C1-6alkyl)2, —S(O)2—Ra, C3-10cycloalkyl, and 3-10 membered heterocyclyl, wherein
the C1-6alkyl of Rc is optionally substituted with one or more —S(O)2—C1-6alkyl,
the C3-10cycloalkyl of Rc is optionally substituted with one or more —OH or C1-6alkyl, and
the 3-10 membered heterocyclyl of Rc is optionally substituted with one or more —OH or C1-6alkyl, and wherein
the C1-6alkyl of the 3-10 membered heterocyclyl of Rc is further optionally substituted with one or more —OH;
Ra is, independently at each occurrence:
(i) C1-6alkyl optionally substituted with one or more halo, —OH, —S(O)2—C1-6alkyl, or —N(C1-6alkyl)-C(O)—C1-6alkyl,
(ii) C3-10cycloalkyl optionally substituted with one or more —OH, —C(O)2—C1-6alkyl, —C(O)—NH(C1-6alkyl), —C(O)—N(C1-6alkyl)2, or —C(O)—C3-10heterocyclyl, or C1-6alkyl, wherein
the C1-6alkyl is optionally substituted with one or more —OH,
(iii) 3-10 membered heterocyclyl optionally substituted with one or more C1-6alkyl, or
(iv) NH(C1-6alkyl);
R5 is, independently at each occurrence, H, halo, —CN, 3-10 membered heterocyclyl, C1-6alkyl, or C1-6alkoxy, wherein
the C1-6alkyl of R5 is optionally substituted with one or more halo or —OH, and
the C1-6alkoxy of R5 is optionally substituted with one or more halo; and
R6 and R7 are each independently H or halo.